拉唑类三联疗法治疗幽门螺杆菌感染的成本-效果分析  

Cost Effectiveness Analysis of the Treatment of Helicobacter Pylori Infection by Triple Therapy

作　　者：孙洁[1] 鲁逊艳 

机构地区：[1]枣庄市立医院药剂科,277100 [2]枣庄市王开传染病医院,277100

出　　处：《中国继续医学教育》2015年第24期145-146,共2页China Continuing Medical Education

摘　　要：目的探讨拉唑类三联疗法治疗幽门螺杆菌感染的成本-效果。方法选择我院收治的196例Hp感染消化道溃疡患者随机分为RAC组、OAC组和LAC组,对比三组临床疗效。结果三组Hp根除率和临床症状改善情况对比无明显的统计学差异(P>0.05)。结论幽门螺杆菌感染患者接受拉唑类三联疗法治疗效果显著。Objective To explore the cost-effectiveness of triple therapy for helicobacter pylori infection. Methods 196 patients with Hp infection in our hospital were randomly divided into RAC group, OAC group and LAC group, the clinical efficacy of the three groups were compared.Results There was no signiifcant difference between the three groups in Hp eradication rate and clinical symptom improvement （P〉0.05）. Conclusion The treatment effect of the triple therapy combined with helicobacter pylori infection in patients with helicobacter pylori infection can be promoted signiifcantly.

关 键 词：拉唑类三联疗法 幽门螺杆菌感染 成本-效果 

分 类 号：R573.1[医药卫生—消化系统]